seaweed drug

China’s ‘Seaweed’ Alzheimer’s Drug Is Now Available to Patients

By Lecia Bushak | December 30th, 2019

An experimental “seaweed” drug called Oligomannate, which treats Alzheimer’s, is now available for patients to buy in China.

Chinese officials announced conditional approval to a seaweed-based drug in November. Now, it’s available on the Chinese market. Oligomannate is the first drug to be approved for the treatment of Alzheimer’s in 17 years. The drug is produced by Shanghai Green Valley Pharmaceutical Company, and comes in a 150 milligram capsule. It could cost up to 3,580 yuan — or $512 — for just a month’s worth of treatment, according to the South China Morning Post.

Gut bacteria and the brain

Instead of attacking amyloid-beta or tau protein in the brain, researchers claim that Oligomannate works by tinkering with gut bacteria, which can lead to reduced inflammation in the brain. In previous research, researchers concluded that a sugar in Oligomannate suppresses bacteria that can cause cell degeneration and inflammation in the brain.

Vincent Mok, who heads the neurology division at the Chinese University of Hong Kong, said that the new drug showed “encouraging results” when compared to acetylcholinesterase inhibitors—the existing treatment for mild to severe Alzheimer’s.

“It is just as effective but it has fewer side effects,” Mok said in an interview with CNN. “It will also open up new avenues for Alzheimer’s research, focusing on the gut microbiome.”

Skepticism of the ‘seaweed’ drug

The past year has been an interesting one for the field of Alzheimer’s research, between the cancellation then subsequent resurrection of Biogen’s drug, aducanumab, and the approval of Oligomannate in China. Though some experts remain skeptical about aducanumab, others are touting it as a “milestone achievement” for Alzheimer’s research.

Some experts also question the validity and safety of Oligomannate. Some doctors noted that very little is known about the drug.

Writing an article in a blog for the American Association for the Advancement of Science (AAAS), scientist Derek Lowe noted that “a new Alzheimer’s therapy is already going to face a tough development path and a lot of skepticism, but this one has even more red flags that I had realized.”

According to the South China Morning Post, Geng Meiyu, one of the researchers out of Shanghai Institute of Materia Medica who worked on the drug, said data on lab rats showed the drug was safe.

However, more trials are in store for the drug — with some to be carried out in North America, Europe and Asia and enrolling 2,000 patients with mild-to-moderate Alzheimer’s disease, Green Valley Vice President Li Jinhe announced on Sunday. If the trials are successful, the goal is to make Oligomannate available globally by 2025.

If you find our articles and interviews helpful, please consider becoming a supporting member of our community. Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient. We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.

Please help support our mission.

6 thoughts on “China’s ‘Seaweed’ Alzheimer’s Drug Is Now Available to Patients

  1. Safety of this type of polymer, taken orally, is not likely to be the biggest concern on first sight. Efficacy is a serious concern:
    Geng Meiyu (the “discoverer”) has published papers with major problems in them, like data duplication… discussed further on the Sciencemag blog below… this type of repeated figure duplication is considered fraud in scientific publications (look under links in the sentence “Unfortunately, the comments on other papers from this lab detail what appear to be clear instances of image duplication and overlap in what are supposed to be completely different experiments and samples.”):

  2. I currently have MCI. I am interested in any or all studies I am appropriate for.
    I also would like to purchase seaweed.

    1. Hello Bonnie, China’s Seaweed drug is not available in the US. Consult Your Physician – Being Patient does not give medical advice, nor is any information on the site intended to be prescriptive medical advice. If you have any questions about your health or the health of your loved one, please consult your physician for any and all medical-related questions.

  3. hello, my doctor gave me the prescription of the oligomannate, but I don’t know where to buy online.

    1. Laila, Oligomannate, also known as GV-971 may not yet be approved and available in your country. It is a drug manufactured by Green Valley Pharmaceuticals in Shanghai, China. ~ Thank you.

  4. My name is TSun Jimmy from city: Jakarta, zip: 10150, country: Indonesia.
    Purpose of contact : my mother really suffered on Alzheimer diseases, I have read many information about GV-971 made by seaweed.
    Regarding on my mother suffering, wether would you please tell me, how to purchase and for me lived outside China, how to order that G-971 ?

Leave a Reply

We are glad you have chosen to leave a comment. Please keep in mind that comments are moderated according to our comment policy.